L-Metaraminol
L-Metaraminol Brand names, L-Metaraminol Analogs
L-Metaraminol Brand Names Mixture
- No information avaliable
L-Metaraminol Chemical_Formula
C9H13NO2
L-Metaraminol RX_link
http://www.rxlist.com/cgi/generic2/metar.htm
L-Metaraminol fda sheet
L-Metaraminol msds (material safety sheet)
L-Metaraminol Synthesis Reference
Brit. pat. 353,361 (1930 to I. G. Farben); Brit. pat. 396,951 (1932 to I. G. Farben); Swiss pat. 162,267 (1931 to I. G. Farben); U.S. pats. 1,948,162 ans 1,951,302; Hartung, U.S. pat. 1,995,709 (1935 to Sharp & Dohme)
L-Metaraminol Molecular Weight
167.205 g/mol
L-Metaraminol Melting Point
107.5 oC
L-Metaraminol H2O Solubility
1000 g/L
L-Metaraminol State
Solid
L-Metaraminol LogP
0.6
L-Metaraminol Dosage Forms
Intramuscular injection; Intravenous injection
L-Metaraminol Indication
For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage
L-Metaraminol Pharmacology
Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol acts on both α1-adrenergic receptors but appears to have no effect on β-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels.
L-Metaraminol Absorption
The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection.
L-Metaraminol side effects and Toxicity
LD50=240 mg/kg (rat, oral); LD50=99 mg/kg (mouse, oral)
L-Metaraminol Patient Information
L-Metaraminol Organisms Affected
Humans and other mammals
